Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...
Allison Baum Gates: What has surprised you the most about how venture capital has changed in 2020? Laura Thompson: I was very surprised about the post-COVID market. What really shocked me from an LP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback